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A b s t r a c t  
Present world scenario globally, upto 2010, around 285 million people suffering from Type 2 
diabetes making up about 90% of the cases. According to statistics, by 2030, this number is 
estimated to almost double. Diabetes mellitus occurs throughout the world, but is more common 
(especially Type 2) in the more developed countries. The greatest increase in prevalence is, 
however, expected to occur in Asia and Africa, where most patients will probably be found by 2030. 
The aim of this review is to summarize several studies done for the discovery of new drug using 
different animal models for in vivo studies (chemical, surgical, and genetic models ) & in vitro models 
(glucose uptake, pancreatic islet cell lines and  insulin secretion). 




Diabetes mellitus is a group of metabolic diseases in which a 
person has high blood sugar, either because the body does not 
produce enough insulin, or because cells do not respond to the 
insulin that is produced. This high blood sugar produces the 
classical symptoms of polyuria (frequent 
urination), polydipsia (increased thirst) and polyphagia (increased 
hunger) [1]                       
There are three main types of diabetes mellitus (DM). Type 1 
DM results from the body's failure to produce insulin, and presently 
requires the person to inject insulin or wear an insulin pump. This 
form was previously referred to as "Insulin-Dependent Diabetes 
Mellitus" (IDDM) or "Juvenile Diabetes". Type 2 DM results 
from insulin resistance, a condition in which cells fail to use insulin 
properly, sometimes combined with an absolute insulin deficiency. 
This form was previously referred to as Non Insulin-Dependent 
Diabetes Mellitus (NIDDM) or "Adult-Onset Diabetes". The third 
main form, gestational diabetes occurs when pregnant women 
without a previous diagnosis of diabetes develop a high blood 
glucose level. It may precede development of Type 2 DM [2]. 
Genetic defects of β-cell function                                                    
Maturity onset diabetes of the young                                                        
Mitochondrial DNA mutations 
Genetic defects in insulin processing or insulin action 
Defects in proinsulin conversion 
 
 
Insulin gene mutations 
Insulin receptor mutations 
Exocrine pancreatic defects                                        
1. Chronic pancreatitis 
2.  Pancreateatectomy 
3.  Pancreaticneoplasia 
4.  Cystic fibrosis 
5. Hemochromatosis 
6.  Fibrocalculous pancreatopathy 
Pathophysiology 
Insulin is the principal hormone that regulates uptake 
of glucose from the blood into most cells (primarily muscle and fat 
cells, but not central nervous system cells). Therefore, deficiency of 
insulin or the insensitivity of its receptors plays a central role in all 
forms of diabetes mellitus Insulin is also the principal control signal 
for conversion of glucose to glycogen for internal storage in liver 
and muscle cells. Lowered glucose levels result both in the 
reduced release of insulin from the β-cells and in the reverse 
conversion of glycogen to glucose when glucose levels fall. This is 
mainly controlled by the hormone glucagon, which acts in the 
opposite manner to insulin. Glucose thus forcibly produced from 
internal liver cell stores (as glycogen) re-enters the bloodstream; 
muscle cells lack the necessary export mechanism. Normally, liver 
cells do this when the level of insulin is low (which normally 
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correlates with low levels of blood glucose). Higher insulin levels 
increase some anabolic ("building up") processes, such as cell 
growth and duplication, protein synthesis, and fat storage. Insulin 
(or its lack) is the principal signal in converting many of the 
bidirectional processes of metabolism from a catabolic to an 
anabolic direction, and vice versa. In particular, a low insulin level 
is the trigger for entering or leaving ketosis (the fat-burning 
metabolic phase) [1]. 
Present word scenario   
Globally, as of 2010, an estimated 285 million people had diabetes, 
with Type 2 making up about 90% of the cases.[3] Its incidence is 
increasing rapidly, and by 2030, this number is estimated to almost 
double. Diabetes mellitus occurs throughout the world, but is more 
common (especially Type 2) in the more developed countries. The 
greatest increase in prevalence is, however, expected to occur in 
Asia and Africa, where most patients will probably be found by 
2030.The increase in incidence in developing countries follows the 
trend of urbanization and lifestyle changes, perhaps most 
importantly a "Western-style" diet. This has suggested an 
environmental (i.e., dietary) effect, but there is little understanding 
of the mechanism(s) at present, though there is much speculation, 
some of it most compellingly presented. [4]  
According to the World Health Organization (WHO), there are 
approximately 160,000 diabetics worldwide, the number of 
diabetics has double in the last few years and is expected to 
double once again in the year 2025 [5]. Due to its high prevalence 
and potential deleterious effect on a patient physical and 
psychological state, diabetes is a major medical concern [6]. In 
India has more diabetics than any other country in the world, 
according to the International Diabetes Foundation, [7]   In India, 
around 50.8 million people are affected by diabetes. It is only in 
China that you will find a greater diabetic population, with 92.4 
million Chinese adults affected by diabetes.  although more recent 
data suggest that China has even more.[8] The disease affects 
more than 50 million Indians - 7.1% of the nation's adults - and kills 
about 1 million Indians a year.[7] The current estimate for 2010 of 
285 million adults with diabetes is 67% higher than the 2004 
published estimate for the year 2000 [9], and our 2030 estimate of 
439 million is 20% higher than the same studyÊs estimate for2030 
[9]. Comparisons with other older estimates show even greater 
differences. 
The economic impacts of diabetes with its complications and 
associated diseases are large [10]. According to recent estimates 
the prevalence of diabetes mellitus is 4% worldwide and that 
indicates 143 million persons are affected which will increase to 
300 million by the year 2025[11]. In urban India, mortality rates are 
twofold higher in people with diabetes compared to non-diabetic 
subjects [12]. It is estimated that the number of diabetes patients 
worldwide will reach 380 million by 2025; Asia, in particular, is 
experiencing a rapidly emerging diabetes epidemic [13]. It has 
been estimated that the global burden of type 2 diabetes mellitus 
(T2DM) for 2010 would be 285 million people (2010) which is 
projected to increase to 438 million in 2030; a 65 % increase . 
Similarly, for India this increase is estimated to be 58%, from 51 
million people in 2010 to 87 million in 2030[14]. 
In-vivo studies 
Chemical induction of diabetes mellitus 
The majority of studies published in the field of ethno 
pharmacology between 1996 and 2006 employed this model. 
Streptozotocin (STZ, 69% and alloxan (31%) are by far the most 
frequently used drugs and this model has been useful for the study 
of multiple aspects of the disease. Both drugs exert their 
diabetogenic action when they are administered parenterally 
(intravenously, intraperitoneally or subcutaneously). The dose of 
these agents required for inducing diabetes depends on the animal 
species, route of administration and nutritional status [15]. 
Streptozotocin model of diabetes mellitus 
Streptozotocin is an antibiotic derived from Streptomyces 
achromogenes and structurally is glucosamine derivative of 
nitrosourea. Rakieten and his associates79 first demonstrated the 
diabetogenic property of STZ in dogs and rats in 1963. 
Streptozotocin prevents DNA synthesis in mammalian and 
bacterial cells. In the bacterial cells, it renders special reaction with 
cytocine groups, resulting in degeneration and destruction of DNA. 
The biochemical Streptozotocin enters the pancreatic cell via a 
glucose transporter-GLUT2 and causes alkylation acid (DNA). 
Furthermore STZ induces activation of poly adenosine diphosphate 
ribosylation and nitric oxide release. As a result of STZ action, 
pancreatic -cells are destroyed by necrosis [16]. In adult rats, 60 
mg/kg is the most common dose of STZ to induce insulin 
dependent diabetes [17], but higher doses are also used. STZ is 
also efficacious after intraperitoneal administration of a similar or 
higher dose, but single doses below 40 mg/kg in adult mice, STZ 
given in multiple lowdoses (40 mg/kg, i.v. for 5 days) [18] induces 
an insulin dependent diabetes that is quite similar to the 
autoimmune forms (islet inflammation and cell death) of Type 1 
diabetes. On the other hand, a single dose between 60 and 100 
mg/kg of STZ [19], administered systemically can also cause 
insulin may be ineffective dependent diabetes, but it lacks the 
autoimmune profile [20]. Recently, a new animal model of Type 2 
diabetes has been produced by combination of STZ and NAD 
administration in adult rats 94. The rats administered NAD (230 
mg/kg, ip) 15 min before STZ (65 mg/kg,iv) has been shown to 
develop moderate and stable non-fasting hyperglycaemia without 
any significant change in plasma insulin level. As NAD is an 
antioxidant which exerts protective effect on the cytotoxic action of 
STZ by scavenging free radicals and causes only minor damage to 
pancreatic beta cell mass producing Type 2 diabetes. Therefore, 
this model is found to be an advantageous tool for investigation of 
insulinotropic agents in the treatment of Type 2 diabetes [21]. 
Sharma et al. International Journal of Advances in Pharmaceutical Sciences 4 (1) 01-08 [2013] 
 
PAGE | 3 |
 
 
Alloxan model of diabetes mellitus 
Alloxan is the also used chemical for induction of diabetes mellitus. 
It is a well- known diabetogenic agent widely used to induce Type 1 
diabetes in animals [22]. Alloxan is a urea derivative which causes 
selective necrosis of the pancreatic islet β-cells. It is used to 
produce experimental diabetes in animals such as rabbits, rats, 
mice and dogs. With this agent, it is possible to produce different 
grades of severity of the disease by varying the dose of alloxan 
used. Thus alloxan induced diabetes mellitus served as a 
pathological biomodel for testing a substance with supposed 
antioxidant activities the most frequently used intravenous dose of 
alloxan in rats is 65mg/kg, but when it is administered 
Intraperitoneally or subcutaneouslyits effective dose must be 
higher.  A solution of 2% alloxan (40mg/kg) diluted in 0.9% normal 
saline was administered to the animals through the iliac vein. The 
animals were allowed to resume feeding and drinking 30 minutes 
after the drug administration. In order to assess the effect of 
alloxan and to chemically establish the diabetic condition, an 
incision was done in any of the four veins in the tail of the rat with a 
15 scapel blade 10 days after induction a blood glucose level was 
determinsd by using a portable glucose analyzer. The most 
frequently used intravenous dose of alloxan in rats is 65mg/kg, but 
when it is administered intraperitoneally or subcutaneously its 
effective dose must be higher [23]. Alloxan administration in 
experimental animals has been reported to produce pancreatic 
lesion which is proportional to the dose of the drug administered. 
And the size of the lesion also correlates with the pancreatic insulin 
content [24].  
Surgical models of diabetes mellitus   
This technique used to induce diabetes is the complete removal of 
the pancreas. Few researchers have employed this model in the 
last years to explore effects of natural products with animal species 
such as rats, pigs, dogs and primates [18,19,25]. Limitations to this 
technique include (1) high level of technical expertise and 
adequate surgical room environment, (2) major surgery and high 
risk of animal infection, (3) adequate post-operative analgesia and 
antibiotic administration, (4) supplementation with pancreatic 
enzymes to prevent malabsorption and (5) loss of pancreatic 
counter regulatory response to hypoglycemia. More recently, 
partial pancreatectomy has been employed, but large resection 
(more than 80% in rats) is required to obtain mild to moderate 
hyperglycemia. In this case, small additional resection can result in 
significant hypoinsulinemia [26]. 
Genetic models of diabetes 
Spontaneously develop diabetic rat - These models permit the 
evaluation of the effect of a natural product in an animal without the 
interference of side effects induced by chemical drugs like alloxan 
and STZ reported above. Example is the spontaneously diabetic 
Goto-Kakizaki rat which is a genetic lean model of type 11 diabetes 
originating from selective breeding over many generations of 
glucose-intolerant nondiabetic wistar rats [27]. Regarding type1 
diabetes models, the mouse typically presents hyperglycemia 
between 12 and 30 weeks of age, whereas in BB rats it occurs 
around 12 weeks of age. One great advantage of these models is 
that they can be employed as model of atherosclerosis which 
represents the long term complication of diabetes mellitus and 
tested against several natural products [28].  
Genetically engineered diabetic mice 
Although significant advances in this field have arisen in recent 
years, especially with the advent of transgenic mice, In this case, 
rodents may be produced to over (transgenic) or under (knockout)-
express proteins thought to play a key part in glucose metabolism 
[25,29]. There have been no studies carried out involving natural 
products and these models. Certainly, the high costs restrict their 
study in sophisticated protocols which explore mechanisms of 
potential therapeutic agents that either stimulate pancreatic cell 
growth or inhibit pancreatic cell death [31]. Von Herrath and 
Oldstone (1997) [31] infected mice with lymphocytic 
choriomeningitis virus (LCMV) to induce IDDM. Similarly, Oldstone 
et al.(1991) developed a transgenic mouse model that expressed 
IDDM by inserting a viral gene in the animal egg stage[32]. 
In-vitro studies on insulin secretion  
Conventional antidiabetic agents can affect several pathways of 
glucose metabolism such as insulin secretion, glucose uptake by 
target organs as well as nutrient absorption. Recently, incretins 
[33], and transcription factors such as peroxisome proliferator-
activated receptors·PPAR are targets of modern therapy. Insulin 
receptor, glucose transport ers, however, has not been yet the 
focus of antidiabetic therapy. Although few studies using natural 
products have been published [34, 35, 37], 
Studies using insulin-secreting cell lines  
Bioengineered technologies have provided new opportunities to 
improve and establish more appropriate cultured cell lines help to 
facilitate studies of mechanisms of both insulin secretion and cell 
dysfunction, being also the target to the study of natural products. 
The most widely used insulin-secreting cell lines are RIN, HIT, 
beta-TC, MIN6 and INS-1 cells. These cell lines release mainly  
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Table 1 Comparison of Type 1 and 2 Diabetes 
Feature Type 1 Diabetes Type 2 Diabetes 
Age at onset In children In adults 
Onset Sudden Gradual 
Body habitus Thin or normal Often obese 
Endogenous insulin Low or absent Increased , decreased or normal 
Prevalence ~10% ~90% 
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insulin and small amounts of glucagon and somatostatin. Although 
the behaviour of none of these cell lines perfectly mimics primary 
cell physiology, they are extremely valuable tools for the study of 
molecular events underlying cell function [37] 
Studies using isolated pancreatic islet cell lines 
Diabetic rat or mouse that can be obtained by collagenase 
diagetion technique followed by adequate separation. These 
pathway can be studied with isolated pancreatic β-cells from either 
control or & transference to appropriated culture medium [38]. It is 
known that insulin secretion occurs when pancreatic cells utilize 
glucose to generate adenosine triphosphate (ATP) from adenosine 
diphosphate (ADP) [39]. The resulting increase in cytoplasmic 
ATP/ADP ratio closes ATP-sensitive potassium channels, causing 
depolarization of the plasma membrane, which activates voltage-
dependent Ca2+ channels. This results in elevation of the 
intracellular Ca2+ concentration which triggers insulin secretion 
[40]. In type 2 diabetes, pancreatic cells exhibit atypical ion channel 
activity and an abnormal pattern of insulin secretion [41]. These 
pathways can be studied with isolated pancreatic cells from either 
control or diabetic rat or mouse that can be obtained by 
collagenase digestion technique, followed by adequate separation 
and transference to appropriated culture medium [35,36]. 
Afterwards, the experimental protocol is assayed. 
In-vitro studies on glucose uptake  
Adipose tissue is considered a key link between obesity and Type 
2 diabetes by promoting the development of lipotoxicity, i.e. cell 
damage as a consequence of elevated intracellular lipid 
concentrations and insulin resistance [41]. Insulin resistance either 
at the adipocyte or skeletal muscle levels contribute to 
hyperglycemia. However, adipocytes from different sites of the 
body may have different biological or pathological effects. 
Pathways related to insulin resistance may be studied in cell lines 
of adipocytes such as marine 3T3-L1 cells [42] and rat L6 muscle 
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tools to evaluate the effects of natural products upon glucose 
uptake.  
Models of diabetes accelerated atherosclerosis 
Accelerated cardiovascular disease is a leading cause of both 
morbidity and mortality in diabetic patients [44]. Aggressive therapy 
of dyslipidemia is necessary, since the risk of myocardial infarction 
is the same as in nondiabetic patients with previous myocardial 
infarction [45]. Currently, rats and mice are the most widely used 
models to study diabetes and atherosclerosis. Albeit, diabetic mice 
do not exhibit a high degree of atherosclerosis unless 
hyperglycemia is associated with severe hyperlipidemia, a fat diet 
is also present in these protocols. Models of diabetic nephropathy, 
a microvascular complication have also been developed [44,46]. 
Oral therapeutics for Diabetes Mellitus 
The available therapeutic options for diabetes mellitus target 
several major sites of action. The pancreas, because it regulates 
insulin secretion, is a critical organ in the development of diabetes 
mellitus. The liver is responsible for glucose production, making it a 
second important target organ in the treatment of diabetes. The 
intestine mediates glucose absorption into the body, whereas 
adipose tissue and muscle are active in peripheral glucose uptake. 
Dysfunction in any one of these organs has been implicated in the 
development of diabetes mellitus. In response, a diverse array of 
oral therapeutics has been developed. Sulfonylureas, repaglinide, 
and nateglinide are insulin secretagogues that stimulate 
endogenous insulin secretion from the pancreas [47] and are used 
as hypoglycemic agents for the treatment of Type 2 diabetes. 
These agents also improve insulin sensitivity as a result of 
improved glucose control. The adverse effects of sulfonylureas 
include severe hypoglycemia (in the event of an overdose), weight 
gain, erythema, and hepatic dysfunction [48]. Repaglinide and 
nateglinide, which are meglitinide analogs, decrease ATP-sensitive 
K+ conductance in a glucose-dependent manner. They are taken 
with meals to prevent postprandial hyperglycemia and to reduce 
the risk of long-lasting hypoglycemia. Both sulfonylureas and 
meglitinides can induce weight gain [49]. 
Conclusion   
Inspite of the worldwide use of herbs and medicinal plants, the 
effective treatment of diabetes with phytochemicals has not been 
validated with scientific criteria which may support their substitution 
for the current therapy. None of the known single species is exactly 
equivalent to human diabetes, but each model act as essential tool 
for investigating genetic, endocrine, metabolic, morphologic 
changes and underlying aetiopathogenic mechanisms that could 
also operate during the evolution of Type 2 diabetes in humans. 
The selection of particular animal model is particularly depending 
on the investigatorÊs choice whether to use inbred or out bred, 
availability of particular strain, aim of scientific strategy, type of 
drug being sought, institutional financial and facility resources in 
the Type 2 diabetes research and pharmaceutical drug discovery 
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